CONMED Corp. 10-Q Summary: Quarter Ended September 30, 1998
Business Context and Reporting Period
This Form 10-Q covers the three and nine months ended September 30, 1998. CONMED Corporation is a leading developer and manufacturer of medical instruments and systems, including electrosurgical systems, ECG electrodes, and wound care products. The reporting period is significantly impacted by the December 31, 1997, acquisition of Linvatec Corporation, which expanded the company's portfolio into arthroscopic surgery, powered surgical instruments, and imaging products.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended Sept 1998 | 9 Months Ended Sept 1998 |
|---|---|---|
| Net Sales | $85,714 | $246,469 |
| Cost of Sales | $41,121 | $126,377 |
| Gross Margin % | 52.0% | 48.7% |
| Operating Income | $17,060 | $43,175 |
| Net Income | $5,921 | $11,350 |
| Diluted EPS | $0.74 | $0.74 |
| Cash from Operations | N/A | $14,039 |
| Total Debt (Current + Long-term) | $364,629 | $364,629 |
| Cash and Equivalents | $3,290 | $3,290 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 122% for the quarter and 145% for the nine-month period compared to 1997, driven principally by the Linvatec acquisition.
- Profitability: Net income rose 31% for the quarter and 9% for the nine-month period. Gross margins improved to 52.0% in Q3 1998 from 44.0% in Q3 1997 due to Linvatec's higher-margin products.
- Interest Expense: Interest expense surged to $7.8 million for the quarter (from $0.1 million income in 1997) and $23.0 million for the nine months (from $0.8 million income in 1997) due to debt incurred to finance the Linvatec acquisition.
- Working Capital: Accounts receivable increased by $9.7 million and inventories by $14.8 million during the nine-month period, reflecting the expansion of international sales and distribution operations.
- Extraordinary Item: The nine-month 1998 results include a $1.6 million net-of-tax extraordinary charge related to the write-off of deferred financing fees from a subordinated note offering.
Guidance, Outlook, and Risks
Management Commentary: Management attributes the significant increase in sales and operating expenses to the Linvatec acquisition. Selling and administrative expenses as a percentage of sales increased to 28.6% in Q3 1998, reflecting the higher cost structure of the acquired business. The company completed a $130 million subordinated note offering in March 1998 to reduce term loans.
Liquidity: As of September 30, 1998, the company had $84 million available under its $100 million revolving credit facility. Management believes cash from operations and available credit are sufficient for working capital and debt service.
Risks and Contingencies:
- Year 2000 Compliance: The company is upgrading IT systems to be Year 2000 compliant by March 31, 1999. While costs are not currently expected to be material, failure of critical systems or third-party failures could have a material adverse effect.
- Debt Covenants: The Credit Facility and subordinated notes contain restrictive covenants regarding working capital, financial ratios, and dividend payments.
- Subsequent Event: On October 8, 1998, the company entered an agreement to acquire arthroscopy products for approximately $17.5 million, expected to close in November 1998.
Investor Verification Checklist
- Verify the integration progress and revenue contribution of the Linvatec acquisition versus initial projections.
- Monitor the company's ability to service its high debt load ($364.6 million total) given the significant interest expense.
- Confirm the status of Year 2000 remediation efforts and any potential costs or disruptions from third-party vendors.
- Review the impact of the $17.5 million subsequent acquisition on future cash flow and leverage ratios.
- Assess the sustainability of the 52.0% gross margin, noting the one-time inventory step-up adjustment that reduced the nine-month margin by 1.2 percentage points.